Oral semaglutide and survival in heart failure with preserved ejection fraction and type 2 diabetes
Kishimori T, Kato T, Iwasaki Y, et al.
Diabetes Obes Metab. Pub. online 5 Jan 2026.
Leggi
Breaking news
Sex differences in trial representation and the cardiovascular effectiveness of newer glucose-lowering agents in patients with and without type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Zawadka M, Taguiam E, Lê ML, et al.
Diabetes Obes Metab. Pub. online 8 Jan 2026.
Leggi
Effectiveness of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists on diabetic foot disease : an emulated target trial
Kristensen FPB, Christensen DH, Callaghan BC, et al.
Ann Intern Med. Pub. online 6 Jan 2026.
Leggi
Where is the social in the psychosocial? A narrative review
Cleal B, Skovlund S, Skinner TC, O’Donnell S
Diabet Med. Pub. online 29 Dec 2025.
Leggi
Relationship between patient activation, experienced stigma, and internalised weight stigma in people with type 2 diabetes
Sims TJ, Kapoor R, Chinthammit C, Spaepen E
Diabet Med. 2025:e70190.
Leggi
AIFA. Nota Informativa Importante sulla cessazione temporanea della commercializzazione di Insulina Lispro Sanofi
17 dicembre 2025
Leggi
AIFA: Disponibile “OsMed interattivo”, aggiornato con i dataset più recenti su consumi e spesa dei farmaci in Italia
19 dicembre 2025
Leggi
Digital twin paradigm in diabetes prediction and management
Olawade DB, Owhonda RC, Alabi JO, et al.
Diabetes Res Clin Pract. Pub. online 29 Dec 2025.
Leggi
Effect of digital interventions on adherence to the management of type 1 diabetes mellitus patients: a systematic review
Jawad M, Afaq S, Hussain S, et al.
BMC Endocr Disord. Pub. online 30 Dec 2025.
Leggi
GLP-1 receptor agonist use during immune checkpoint inhibitor therapy is associated with mortality and immune-related adverse events across cancer types in people with type 2 diabetes: a target-trial emulation
Chan SH, Li PY, Li PH, et al.
Diabetes Res Clin Pract. 2025:113073.
Leggi